135 related articles for article (PubMed ID: 30640960)
21. Correction: IFN-γ Stimulates Autophagy-Mediated Clearance of Burkholderia cenocepacia in Human Cystic Fibrosis Macrophages.
Assani K; Tazi MF; Amer AO; Kopp BT
PLoS One; 2019; 14(2):e0213092. PubMed ID: 30807600
[TBL] [Abstract][Full Text] [Related]
22. Correction: Pyrosequencing Unveils Cystic Fibrosis Lung Microbiome Differences Associated with a Severe Lung Function Decline.
Bacci G; Paganin P; Lopez L; Vanni C; Dalmastri C; Cantale C; Daddiego L; Perrotta G; Dolce D; Morelli P; Tuccio V; De Alessandri A; Fiscarelli EV; Taccetti G; Lucidi V; Bevivino A; Mengoni A
PLoS One; 2016; 11(8):e0160726. PubMed ID: 27478895
[TBL] [Abstract][Full Text] [Related]
23. Small colony variants of Pseudomonas aeruginosa in chronic bacterial infection of the lung in cystic fibrosis.
Evans TJ
Future Microbiol; 2015; 10(2):231-9. PubMed ID: 25689535
[TBL] [Abstract][Full Text] [Related]
24. Long-Term Microevolution of Pseudomonas aeruginosa Differs between Mildly and Severely Affected Cystic Fibrosis Lungs.
Klockgether J; Cramer N; Fischer S; Wiehlmann L; Tümmler B
Am J Respir Cell Mol Biol; 2018 Aug; 59(2):246-256. PubMed ID: 29470920
[TBL] [Abstract][Full Text] [Related]
25. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
Ciofu O
APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
[TBL] [Abstract][Full Text] [Related]
26. Correction: Impact of extensive antibiotic treatment on faecal carriage of antibiotic-resistant enterobacteria in children in a low resistance prevalence setting.
Knudsen PK; Brandtzaeg P; Høiby EA; Bohlin J; Samuelsen Ø; Steinbakk M; Abrahamsen TG; Müller F; Gammelsrud KW
PLoS One; 2018; 13(2):e0193439. PubMed ID: 29466441
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Balke B; Hogardt M; Schmoldt S; Hoy L; Weissbrodt H; Häussler S
Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):25-30. PubMed ID: 16402226
[TBL] [Abstract][Full Text] [Related]
28. In Vitro Antibiotic Susceptibility of Initial Pseudomonas aeruginosa Isolates From United States Cystic Fibrosis Patients.
VanDevanter DR; Van Dalfsen JM; Burns JL; Mayer-Hamblett N
J Pediatric Infect Dis Soc; 2015 Jun; 4(2):151-4. PubMed ID: 26407415
[TBL] [Abstract][Full Text] [Related]
29. Genotypic and phenotypic analyses of a Pseudomonas aeruginosa chronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains.
Varga JJ; Barbier M; Mulet X; Bielecki P; Bartell JA; Owings JP; Martinez-Ramos I; Hittle LE; Davis MR; Damron FH; Liechti GW; Puchałka J; dos Santos VA; Ernst RK; Papin JA; Albertí S; Oliver A; Goldberg JB
BMC Genomics; 2015 Oct; 16():883. PubMed ID: 26519161
[TBL] [Abstract][Full Text] [Related]
30. Genotypic Diversity within a Single Pseudomonas aeruginosa Strain Commonly Shared by Australian Patients with Cystic Fibrosis.
Tai AS; Bell SC; Kidd TJ; Trembizki E; Buckley C; Ramsay KA; David M; Wainwright CE; Grimwood K; Whiley DM
PLoS One; 2015; 10(12):e0144022. PubMed ID: 26633539
[TBL] [Abstract][Full Text] [Related]
31. Multi-resistant Pseudomonas aeruginosa ST235 in cystic fibrosis.
Lee AC; Jones AL
Paediatr Respir Rev; 2018 Jun; 27():18-20. PubMed ID: 29914746
[TBL] [Abstract][Full Text] [Related]
32. Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance.
Sousa AM; Monteiro R; Pereira MO
Int J Med Microbiol; 2018 Dec; 308(8):1053-1064. PubMed ID: 30377031
[TBL] [Abstract][Full Text] [Related]
33. Relevance of multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis.
Stefani S; Campana S; Cariani L; Carnovale V; Colombo C; Lleo MM; Iula VD; Minicucci L; Morelli P; Pizzamiglio G; Taccetti G
Int J Med Microbiol; 2017 Sep; 307(6):353-362. PubMed ID: 28754426
[TBL] [Abstract][Full Text] [Related]
34. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation.
Saiman L; Mehar F; Niu WW; Neu HC; Shaw KJ; Miller G; Prince A
Clin Infect Dis; 1996 Sep; 23(3):532-7. PubMed ID: 8879776
[TBL] [Abstract][Full Text] [Related]
35. Rhesus θ-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa.
Beringer PM; Bensman TJ; Ho H; Agnello M; Denovel N; Nguyen A; Wong-Beringer A; She R; Tran DQ; Moskowitz SM; Selsted ME
J Antimicrob Chemother; 2016 Jan; 71(1):181-8. PubMed ID: 26433781
[TBL] [Abstract][Full Text] [Related]
36. Correction: Assessing the consistency of iPSC and animal models in cystic fibrosis modelling: A meta-analysis.
Darwish T; Al-Khulaifi A; Ali M; Mowafy R; Arredouani A; Doi SA; Emara MM
PLoS One; 2024; 19(2):e0299166. PubMed ID: 38354208
[TBL] [Abstract][Full Text] [Related]
37. Vaccines for preventing infection with Pseudomonas aeruginosa in people with cystic fibrosis.
Keogan MT; Johansen HK
Cochrane Database Syst Rev; 2000; (2):CD001399. PubMed ID: 10796780
[TBL] [Abstract][Full Text] [Related]
38. Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients.
Finklea JD; Hollaway R; Lowe K; Lee F; Le J; Jain R
Diagn Microbiol Infect Dis; 2018 Sep; 92(1):75-77. PubMed ID: 29884565
[TBL] [Abstract][Full Text] [Related]
39. The social network of cystic fibrosis centre care and shared Pseudomonas aeruginosa strain infection: a cross-sectional analysis.
Kidd TJ; Soares Magalhães RJ; Paynter S; Bell SC;
Lancet Respir Med; 2015 Aug; 3(8):640-50. PubMed ID: 26208994
[TBL] [Abstract][Full Text] [Related]
40. Treating resistant Pseudomonas aeruginosa lung disease in young children with cystic fibrosis.
Lim SZP; Fitzgerald DA
Paediatr Respir Rev; 2018 Jun; 27():33-36. PubMed ID: 29033215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
